Phase to Phase: Navigating Drug Combinations with Hypomethylating Agents in Higher-risk MDS Trials for Optimal Outcomes

Management of myelodysplastic neoplasms (MDS) is a multifaceted challenge that requires a personalized approach, aimed at enhancing both the quality of life and longevity for each patient. Considering the broad heterogeneity in clinical outcomes, it is crucial to adopt a personalized, patient-centered treatment approach and for assessment of therapy success [1]. Risk stratification with the Revised International Prognostic Scoring System (IPSS-R) classifies patients into two primary categories, lower-risk MDS (LR MDS) and higher-risk MDS (HR MDS) [2 –3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research